PE-121 : Lack of inhaled bronchodilator treatment effect in the bronchiectasis patients with restrictive spirometric pattern

Purpose: The recognition of bronchiectasis is growing with increasing prevalence. Recent retrospective study showed the benefit of lung function improvement with use of bronchodilator in bronchiectasis patients with obstructive spirometric pattern. However, there was no available study to evaluate the effect of bronchodilator therapy to the bronchiectasis patients with pure restrictive spirometric pattern (RSP). Thus, we aimed to evaluate the effect of bronchodilator therapy in patients with bronchiectasis and RSP. Method: A retrospective review of bronchiectasis patients diagnosed by chest computed tomography (CT) scan from January 2015 to December 2018 was performed and 356 patients showed pure RSP. Among them, 124 patients received inhaled bronchodilator therapy and performed lung function tests within 1 year before the therapy and after 3-12 months of the therapy. We compared pre and post-treatment lung function of these 124 patients. Result: The median age of the patients was 63 years and 54% of patients (67/124) were male. The median duration of inhaler therapy was 6.1 months. In PFT, the median baseline forced expiratory volume in the first second (FEV1), forced vital capacity (FVC), and ratio of FEV1/FVC were 1.68L/62.5% predicted, 2.14L/62.0% predicted, and 77.0%, respectively. After bronchodilator therapy, the median FEV1, FVC, and FEV1/FVC were 1.72L/62.0% predicted, 2.15L/61.0% predicted and 76.0%, respectively, without significant change of lung function after inhaler therapy. Conclusion: The effect of the bronchodilator might be limited in bronchiectasis patients with pure restrictive spirometric pattern.